Oculis drops DME programme

Oculis has dropped its diabetic macular edema program for OCS-01 after two pivotal Phase 3 trials failed on the measure that mattered for approval: vision. The Swiss ophthalmology company said May 30 that both studies in the DIAMOND program missed their prespecified primary endpoint, a mean change in best-corrected visual acuity at week 52. (investors.oculis.com) The decision ends what had been one of the more closely watched attempts to treat DME with an eye drop rather than injections or implants. Oculis said it does not currently plan to pursue a regulatory filing in the indication. ### Which trials failed, and what exactly did they miss? The DIAMOND program consisted of two Phase 3, double-masked, randomized, multicenter trials testing OCS-01 in patients with diabetic macular edema over 52 weeks, Oculis said. (investors.oculis.com) Across the two studies, more than 800 patients were enrolled at 119 investigational sites in the United States and other countries. The primary endpoint in both trials was the mean change in best-corrected visual acuity from baseline to week 52, according to the company’s topline-results release. Oculis said that endpoint was not met in either study. (investors.oculis.com) ### What was OCS-01 supposed to be? OCS-01 is a high-concentration dexamethasone eye drop being developed as a non-invasive treatment for diabetic macular edema, according to Oculis and trade coverage before the readout. The company had presented the program as a potential alternative for patients who need treatment earlier in disease or who respond inadequately to current standard care. (investors.oculis.com) April 20 had looked like a setup for a filing later in 2026. At that point, Oculis said the last patient had completed the final study visit and that topline results were expected in June, with a potential U.S. submission later in the year. That filing plan has now been shelved for DME. (investors.oculis.com) ### Did the drug show anything positive? Oculis said OCS-01 produced a rapid and sustained reduction in retinal thickness, even though that anatomical effect did not translate into a statistically successful visual-acuity outcome in the pivotal trials. The company also said the safety profile was consistent with prior studies, with no unexpected findings reported in the topline announcement. (biospace.com) Market coverage after the release focused on that split between anatomy and function. MarketWatch reported that Oculis shares fell 23% on May 30 after the company said it would not pursue an FDA filing for the treatment. (biospace.com) ### Why had this program drawn attention in retina? Diabetic macular edema is commonly treated with intravitreal injections, making any credible topical approach notable because it could reduce procedure burden if it worked. European Biotechnology described OCS-01 as Oculis’ most advanced ophthalmology program and said the Phase 3 miss removed a hoped-for non-invasive option in DME. (marketbeat.com) The company’s own earlier materials had framed OCS-01 as a possible first topical treatment for DME. That prospect helped distinguish the program from more conventional retinal drug development, which has largely relied on injections, implants or systemic approaches. (marketwatch.com) ### What happens next for Oculis? Oculis said in its May 30 release that it does not currently plan to file OCS-01 for diabetic macular edema with the FDA. The company did not announce another Phase 3 attempt, a partner-led rescue, or a revised DME development timetable in the materials reviewed. (european-biotechnology.com) May 30 is now the key date in the program’s timeline: six weeks after Oculis said final patient visits were complete, the company reported the DIAMOND miss and ended plans for a DME filing. Any next step will likely come through a future company update or securities filing rather than the Phase 3 program itself. (investors.oculis.com) (biospace.com)